These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30227844)

  • 61. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
    Tang Z; Kang M; Zhang B; Chen J; Fang H; Ye Q; Jiang B; Wu Y
    Tumori; 2017 May; 103(3):286-291. PubMed ID: 28058713
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
    Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Notch4 inhibition suppresses invasion and vasculogenic mimicry formation of hepatocellular carcinoma cells.
    Cheng R; Cai XR; Ke K; Chen YL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):719-725. PubMed ID: 29058285
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition.
    Lv G; Tan Y; Lv H; Fang T; Wang C; Li T; Yu Y; Hu C; Wen W; Wang H; Yang W
    Sci China Life Sci; 2017 Nov; 60(11):1203-1213. PubMed ID: 28812296
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
    Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
    Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression.
    Xiao JN; Yan TH; Yu RM; Gao Y; Zeng WL; Lu SW; Que HX; Liu ZP; Jiang JH
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):981-990. PubMed ID: 28271214
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway.
    Fang Y; Liu G; Xie C; Qian K; Lei X; Liu Q; Liu G; Cao Z; Fu J; Du H; Liu S; Huang S; Hu J; Xu X
    Biomed Pharmacother; 2018 May; 101():910-919. PubMed ID: 29635900
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
    Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 74. c-Met/MAPK pathway promotes the malignant progression of residual hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Jia G; Li F; Tong R; Liu Y; Zuo M; Ma L; Ji X
    Med Oncol; 2020 Nov; 37(12):117. PubMed ID: 33215351
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
    Miyauchi Y; Yasuchika K; Fukumitsu K; Ishii T; Ogiso S; Minami T; Kojima H; Yamaoka R; Katayama H; Kawai T; Yoshitoshi-Uebayashi EY; Kita S; Yasuda K; Sasaki N; Uemoto S
    Sci Rep; 2017 Aug; 7(1):9827. PubMed ID: 28851916
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.
    Zhou Y; Liu X; Zhang W; Xu Y; Zhang Q; Xiong S; Tang H; Luo B
    Int J Hyperthermia; 2023; 40(1):2174709. PubMed ID: 36755436
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
    Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
    Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway.
    Xu WL; Wang SH; Sun WB; Gao J; Ding XM; Kong J; Xu L; Ke S
    BMB Rep; 2019 Apr; 52(4):277-282. PubMed ID: 30940322
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
    Zhao Z; Wu J; Liu X; Liang M; Zhou X; Ouyang S; Yao J; Wang J; Luo B
    Cancer Lett; 2018 May; 421():73-81. PubMed ID: 29458142
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Blocking TGFβR synergistically enhances anti-tumor effects of anti-PD-1 antibody in a mouse model of incomplete thermal ablation.
    Ju S; Duan X; Wang Y; Zhang M; Bai Y; He X; Wang C; Liu J; Yao W; Zhou C; Xiong B; Zheng C
    Int Immunopharmacol; 2024 Sep; 138():112585. PubMed ID: 38950456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.